Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRUMP: Targeted Therapy or Immunotherapy in Advanced NSCLC
NCT03574402Phase 2Unknown
- Sponsor
- Guangdong Association of Clinical Trials
- Start
- Jul 2018
- Primary completion
- Dec 2022
- Modality
- Fragment-Derived Small Molecules, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of abivertinib, afatinib, tucidinostat, crizotinib, ensartinib in non-small cell lung cancer (NSCLC), sponsored by Guangdong Association of Clinical Trials. Status: unknown.
02
Drugs
abivertinibafatinibtucidinostatcrizotinibensartinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03574402.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03574402.